ADAM Trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in Merkel cell carcinoma patients with lymph node metastases; NCT03271372
Titel:
ADAM Trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in Merkel cell carcinoma patients with lymph node metastases; NCT03271372
Auteur:
Chen, Wenwen Bhatia, Shailender Brohl, Andrew S. Chandra, Sunandana Dakhil, Sumia Fecher, Leslie A. Gao, Ling Gooley, Ted A. Hanna, Glenn J. Hibbert, Reina Kelly, Ciara M. Kiriluk, Samantha M. Lewis, Karl Moschos, Stergios Nghiem, Paul Thompson, John A. Tykodi, Scott S.